- Home
- MNRO vs AUTL Comparison
MNRO vs AUTL Comparison
Compare MNRO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNRO | AUTL |
|---|---|---|
| Founded | 1957 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.8M | 407.2M |
| IPO Year | 1994 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MNRO | AUTL |
|---|---|---|
| Price | $16.57 | $1.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $16.00 | $8.50 |
| AVG Volume (30 Days) | 698.1K | ★ 1.3M |
| Earning Date | 05-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,195,334,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | $1.59 | $53.96 |
| P/E Ratio | $68.19 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $12.24 | $1.18 |
| 52 Week High | $23.91 | $2.70 |
Technical Indicators
Market Signals| Indicator | MNRO | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 54.85 |
| Support Level | $16.19 | $1.39 |
| Resistance Level | $17.06 | $1.69 |
| Average True Range (ATR) | 0.79 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 19.46 | 54.17 |
Price Performance
Historical ComparisonAbout MNRO Monro Inc.
Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.